Drug Profile

C4X 3256

Alternative Names: C4X-3256; INDV-2000

Latest Information Update: 25 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator C4X Discovery
Developer C4X Discovery; Indivior
Class Drug withdrawal therapies; Small molecules
Mechanism of Action Orexin receptor type 1 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Opioid-related disorders
Phase I Substance-related disorders

Most Recent Events

10 Jun 2024 Indivior plans an End-of-phase I meeting with the US FDA for Opioid-related disorders in the fourth quarter of 2023
10 Jun 2024 Phase-II clinical trials in Opioid-related disorders in USA (PO) (NCT06384157)
03 Jun 2024 Phase-I clinical trials in Opioid-related disorders in United Kingdom (PO) (ISRCTN15079632)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com